Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: Effects of anxiolytic and cannabinoid drugs

BMC Neuroscience

Volumn 8, Issue , 2007, Pages

  Hayase, Tamaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANXIOLYTIC AGENT; CANNABINOID; CANNABINOID RECEPTOR; DIAZEPAM; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NICOTINE; ONDANSETRON; SEROTONIN 1A ANTAGONIST; VIRODHAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CHRONOLOGY; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; MALE; MAZE TEST; MOUSE; NONHUMAN; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MOTOR ACTIVITY; PHYSIOLOGY; TIME;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CANNABINOIDS; DEPRESSION; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NICOTINE; RECEPTORS, CANNABINOID; TIME FACTORS;

EID: 36148929426     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-8-76     Document Type: Article

References (59)

1. Lerman C Audrain J Orleans CT Boyd R Gold K Main D Caporaso N Investigation of mechanisms linking depressed mood to nicotine dependence Addict Behav 1996, 21:9-19. 10.1016/0306-4603(95)00032-1 8729703
2. West R Hajek P What happens to anxiety levels on giving up smoking? Am J Psychiatry 1997, 154:1589-1592. 9356569
3. Epping-Jordan MP Watkins SS Koob GF Markou A Dramatic decreases in brain reward function during nicotine withdrawal Nature 1998, 393:76-79. 10.1038/30001 9590692
4. Parrott AC Heightened stress and depression follow cigarette smoking Psychol Rep 2004, 94:33-34. 10.2466/PR0.94.1.33-34 15077744
5. Blanchard DC Blanchard RJ Cocaine potentiates defensive behaviors related to fear and anxiety Neurosci Biobehav Rev 1999, 23:981-991. 10.1016/S0149-7634(99)00031-7 10580312
6. Sofuoglu M Dudish-Poulsen S Poling J Mooney M Hatsukami DK The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users Addict Behav 2005, 30:1125-1134. 10.1016/j.addbeh.2004.10.010 15925122
7. Costall B Naylor RJ Anxiolytic potential of 5-HT3 receptor antagonists Pharmacol Toxicol 1992, 70:157-162. 1349746
8. Irvine EE Cheeta S Lovelock C File SE Tolerance to midazolam's anxiolytic effects after short-term nicotine treatment Neuropharmacology 2001, 40:710-716. 10.1016/S0028-3908(00)00211-2 11311899
9. Tucci S Genn RF Marco E File SE Do different mechanisms underlie two anxiogenic effects of systemic nicotine? Behav Pharmacol 2003, 14:323-329. 12838038
10. Berlin I Said S Spreux-Varoquaux O Launay JM Olivares R Millet V Lecrubier Y Puech AJ A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers Clin Pharmacol Ther 1995, 58:444-452. 10.1016/ 0009-9236(95)90058-6 7586937
11. Garcia-Colunga J Miledi R Effects of serotonergic agents on neuronal nicotinic acetylcholine receptors Proc Natl Acad Sci USA 1995, 92:2919-2923. 42330 7708749 10.1073/pnas.92.7.2919
12. Lopez-Valdes HE Garcia-Colunga J Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake Mol Psychiatry 2001, 6:511-519. 10.1038/sj.mp.4000885 11526465
13. Dobelis P Hutton S Lu Y Collins AC GABAergic systems modulate nicotinic receptor-mediated seizures in mice J Pharmacol Exp Ther 2003, 306:1159-1166. 10.1124/jpet.103.053066 12829730
14. Hawkins JW Antidepressant effects of nicotine J Clin Psychiatry 1997, 58:324-325. 9269256
15. Kassel JD Unrod M Smoking, anxiety, and attention: Support for the role of nicotine in attentionally mediated anxiolysis J Abnorm Psychol 2000, 109:161-166. 10.1037/0021-843X.109.1.161 10740949
16. Cheeta S Irvine EE Kenny PJ File SE The dorsal raphe nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses Psychopharmacology (Berl) 2001, 155:78-85. 10.1007/s002130100681 11374339
17. Vazquez-Palacios G Bonilla-Jaime H Velazquez-Moctezuma J Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine Pharmacol Biochem Behav 2004, 78:165-169. 10.1016/ j.pbb.2004.03.002 15159146
18. Pontieri FE Tanda G Orzi F Di Chiara G Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs Nature 1996, 382:255-257. 10.1038/382255a0 8717040
19. Charpantier E Barneoud P Moser P Besnard F Sgard F Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area Neuroreport 1998, 9:3097-3101. 10.1097/00001756-199809140-00033 9804323
20. Siqueira LM Brook JS Tobacco use as a predictor of illicit drug use and drug-related problems in Colombian youth J Adolesc Health 2003, 32:50-57. 10.1016/S1054-139X(02)00534-7 12507801
21. Flugy A Gagliano M Cannizzaro C Novara V Cannizzaro G Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats Eur J Pharmacol 1992, 214:233-238. 10.1016/0014-2999(92)90123-L 1355436
22. Harrison AA Liem YT Markou A Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats Neuropsychopharmacology 2001, 25:55-71. 10.1016/S0893-133X(00)00237-2 11377919
23. Castane A Valjent E Ledent C Parmentier M Maldonado R Valverde O Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence Neuropharmacology 2002, 43:857-867. 10.1016/ S0028-3908(02)00118-1 12384171
24. Balerio GN Aso E Maldonado R Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice Psychopharmacology (Berl) 2006, 184:504-513. 10.1007/s00213-005-0251-9 16416159
25. Zaniewska M McCreary AC Przegalinski E Filip M Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats Eur J Pharmacol 2006, 540:96-106. 10.1016/j.ejphar.2006.04.034 16730696
26. Kimura T Ohta T Watanabe K Yoshimura H Yamamoto I Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor Biol Pharm Bull 1998, 21:224-226. 9556149
27. Katona I Rancz EA Acsady L Ledent C Mackie K Hajos N Freund TF Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission J Neurosci 2001, 21:9506-9518. 11717385
28. Gobbi G Bambico FR Mangieri R Bortolato M Campolongo P Solinas M Cassano T Morgese MG Debonnel G Duranti A Tontini A Tarzia G Mor M Trezza V Goldberg SR Cuomo V Piomelli D Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc Natl Acad Sci USA 2005, 102:18620-18625. 1317988 16352709 10.1073/pnas.0509591102
29. Kathuria S Gaetani S Fegley D Valino F Duranti A Tontini A Mor M Tarzia G La Rana G Calignano A Giustino A Tattoli M Palmery M Cuomo V Piomelli D Modulation of anxiety through blockade of anandamide hydrolysis Nat Med 2003, 9:76-81. 10.1038/nm803 12461523
30. Karanian DA Bahr BA Cannabinoid drugs and enhancement of endocannabinoid responses: Strategies for a wide array of disease states Curr Mol Med 2006, 6:677-684. 10.2174/156652406778194991 17022737
31. Tritto T McCallum SE Waddle SA Hutton SR Paylor R Collins AC Marks MJ Null mutant analysis of responses to nicotine: Deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia Nicotine Tob Res 2004, 6:145-158. 10.1080/14622200310001656966 14982698
32. Gilbert DG Dibb WD Plath LC Hiyane SG Effects of nicotine and caffeine, separately and in combination, on EEG topography, mood, heart rate, cortisol, and vigilance Psychophysiology 2000, 37:583-595. 10.1017/ S0048577200981824 11037035
33. Porcu P Sogliano C Cinus M Purdy RH Biggio G Concas A Nicotine-induced changes in cerebrocortical neuroactive steroids and plasma corticosterone concentrations in the rat Pharmacol Biochem Behav 2003, 74:683-690. 10.1016/S0091-3057(02)01065-1 12543235
34. Suemaru K Yasuda K Cui R Li B Umeda K Amano M Mitsuhashi H Takeuchi N Inoue T Gomita Y Araki H Antidepressant-like action of nicotine in forced swimming test and brain serotonin in mice Physiol Behav 2006, 88:545-549. 10.1016/j.physbeh.2006.05.007 16766001
35. Cruz FC Delucia R Planeta CS Differential behavioral and neuroendocrine effects of repeated nicotine in adolescent and adult rats Pharmacol Biochem Behav 2005, 80:411-417. 10.1016/j.pbb.2004.12.007 15740783
36. Sun B Sterling CR Tank AW Chronic nicotine treatment leads to sustained stimulation of tyrosine hydroxylase gene transcription rate in rat adrenal medulla J Pharmacol Exp Ther 2003, 304:575-588. 10.1124/ jpet.102.043596 12538809
37. Devane WA Dysarz FA 3rd Johnson MR Melvin LS Howlett AC Determination and characterization of a cannabinoid receptor in rat brain Mol Pharmacol 1988, 34:605-613. 2848184
38. Stella N Schweitzer P Piomelli D A second endogenous cannabinoid that modulates long-term potentiation Nature 1997, 388:773-778. 10.1038/42015 9285589
39. Hill MN Gorzalka BB Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress Eur J Pharmacol 2004, 499:291-295. 10.1016/j.ejphar.2004.06.069 15381051
40. Arevalo C de Miguel R Hernandez-Tristan R Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters Pharmacol Biochem Behav 2001, 70:123-131. 10.1016/S0091-3057(01)00578-0 11566149
41. Hayase T Yamamoto Y Yamamoto K Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: Interactions with endogenous cannabinoid receptor ligands Behav Pharmacol 2005, 16:395-404. 10.1097/00008877-200509000-00012 16148444
42. Porter AC Sauer JM Knierman MD Becker GW Berna MJ Bao J Nomikos GG Carter P Bymaster FP Leese AB Felder CC Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor J Pharmacol Exp Ther 2002, 301:1020-1024. 10.1124/ jpet.301.3.1020 12023533
43. Kenny PJ Cheeta S File SE Anxiogenic effects of nicotine in the dorsal hippocampus are mediated by 5-HT1A and not by muscarinic M1 receptors Neuropharmacology 2000, 39:300-307. 10.1016/S0028-3908(99)00114-8 10670425
44. Cheeta S Kenny PJ File SE The role of 5-HT1A receptors in mediating the anxiogenic effects of nicotine following lateral septal administration Eur J Neurosci 2000, 12:3797-3802. 10.1046/j.1460-9568.2000.00246.x 11029650
45. Felder CC Briley EM Axelrod J Simpson JT Mackie K Devane WA Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction Proc Natl Acad Sci USA 1993, 90:7656-7660. 47201 8395053 10.1073/pnas.90.16.7656
46. de Lago E de Miguel R Lastres-Becker I Ramos JA Fernandez-Ruiz J Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence Brain Res 2004, 1007:152-159. 10.1016/ j.brainres.2004.02.016 15064146
47. Boyer CS Petersen DR Enzymatic basis for the transesterification of cocaine in the presence of ethanol: Evidence for the participation of microsomal carboxylesterases J Pharmacol Exp Ther 1992, 260:939-946. 1545406
48. Hayase T Yamamoto Y Yamamoto K Stress-related behavioral alterations accompanying cocaine toxicity: The effects of mixed opioid drugs Nihon Arukoru Yakubutsu Igakkai Zasshi 2000, 35:402-414. 11197874
49. Irvine EE Cheeta S File SE Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine Behav Pharmacol 1999, 10:691-697. 10780511
50. Zarrindast MR Homayoun H Babaie A Etminani A Gharib B Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice Eur J Pharmacol 2000, 407:145-158. 10.1016/S0014-2999(00)00628-2 11050302
51. White JM Behavioral interactions between nicotine and diazepam Pharmacol Biochem Behav 1989, 32:479-482. 10.1016/0091-3057(89)90183-4 2727007
52. Costall B Jones BJ Kelly ME Naylor RJ Onaivi ES Tyers MB Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse Pharmacol Biochem Behav 1990, 36:339-344. 10.1016/0091-3057(90)90414-D 2141423
53. Miyazaki S Imaizumi M Machida H The effects of anxiolytics and anxiogenics on evaluation of learning and memory in an elevated plus-maze test in mice Methods Find Exp Clin Pharmacol 1995, 17:121-127. 7674699
54. Romero J de Miguel R Garcia-Palomero E Fernandez-Ruiz JJ Ramos JA Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function Brain Res 1995, 694:223-232. 10.1016/0006-8993(95)00835-E 8974649
55. Compton DR Martin BR The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity J Pharmacol Exp Ther 1997, 283:1138-1143. 9399986
56. Costa B Giagnoni G Colleoni M Precipitated and spontaneous withdrawal in rats tolerant to anandamide Psychopharmacology (Berl) 2000, 149:121-128. 10.1007/s002139900360 10805606
57. Prior H Schwegler H Marashi V Sachser N Exploration, emotionality, and hippocampal mossy fibers in nonaggressive AB/Gat and congenic highly aggressive mice Hippocampus 2004, 14:135-140. 10.1002/hipo.10166 15058491
58. Porsolt RD Le Pichon M Jalfre M Depression: A new animal model sensitive to antidepressant treatments Nature 1977, 266:730-732. 10.1038/266730a0 559941
59. Alves SH Pinheiro G Motta V Landeira-Fernandez J Cruz AP Anxiogenic effects in the rat elevated plus-maze of 5-HT (2C) agonists into ventral but not dorsal hippocampus Behav Pharmacol 2004, 15:37-43. 10.1097/ 00008877-200402000-00005 15075625